Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

SEC Filing · EFFECT

Enlivex Ltd.

ENLVNASDAQEQUITYCurrent

SEC Filing

Filed Aug 13, 2026Accepted Aug 14, 2026, 12:15 AM EDTCIK 1596812Accession 9999999995-26-002658
Share

Company context

Enlivex is a quality longevity company powered by a prediction markets treasury. The Company is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. In addition to its clinical programs, Enlivex operates a prediction markets treasury strategy built around the Rain protocol, the leading decentralized prediction markets infrastructure on Arbitrum. This dual strategy combines the development of quality longevity therapeutics with exposure to the emerging prediction markets ecosystem.

Current securities

Recent company filings

  1. 6-K filingSep 22, 2026
  2. 424B3 filingAug 17, 2026
  3. SCHEDULE 13G filingAug 13, 2026
  4. 6-K filingAug 11, 2026
  5. F-3 filingAug 6, 2026

As-filed source

Primary evidence